title: Plasma homocysteine levels in renal transplant patients on tacrolimus therapy.
abstract: Increased plasma total homocysteine levels afford an independent risk factor to assess cardiovascular morbidity in patients with normal and impaired renal function, including stable transplant recipients. The purpose of this study was to evaluate plasma homocysteine levels and factors known to influence homocysteine metabolism (folate and Vitamin B(12)) in renal transplanted patients treated with tacrolimus. Plasma homocysteine, serum folate and serum vitamin B(12) concentrations were measured in 18 cadaveric renal transplant patients with stable function both before and 3 months after the renal transplantation. While the mean plasma homocysteine level in the renal transplant group was significantly higher than in the control group, no significant change was observed following renal transplantation under tacrolimus therapy (16.84 +/- 6.43 micromol/L vs 16.02 +/- 6.54 micromol/L). The levels of folate before and after transplantation were considerably lower than the control group; a significant effect of tacrolimus has not been observed (7.32 +/- 4.68 ng/mL and 7.55 +/- 5.20 ng/mL). Serum vitamin B(12) levels in the transplant group were significantly lower than the control group; a significant decline was seen 3 months after the renal transplantation (448.94 +/- 230.03 pg/mL vs 334.38 +/- 240.61 pg/mL). Consequently, although plasma homocysteine levels of renal transplant recipients are higher, a lowering effect of tacrolimus therapy was not observed on plasma homocysteine levels. The lower levels of folate and Vitamin B(12) in the transplant group compared to a control group supports therapy with folate and Vitamin B(12) to decrease homocysteine concentrations.
authors.affiliation: Akdeniz University, Faculty of Medicine, Central Laboratory, Clinical Biochemistry Unit, Antalya, Turkey. halideakbas@akdeniz.edu.tr
authors.forename: S H
authors.initials: SH
authors.lastname: Akbas
authors.forename: M
authors.initials: M
authors.lastname: Tuncer
authors.forename: A
authors.initials: A
authors.lastname: Gurkan
authors.forename: L
authors.initials: L
authors.lastname: Yucetin
authors.forename: A
authors.initials: A
authors.lastname: Yavuz
authors.forename: A
authors.initials: A
authors.lastname: Demirbas
authors.forename: F
authors.initials: F
authors.lastname: Ersoy
authors.forename: M
authors.initials: M
authors.lastname: Gultekin
authors.forename: G
authors.initials: G
authors.lastname: Yakupoglu
authors.forename: M
authors.initials: M
authors.lastname: Akaydin
mesh_terms: D000328:Adult; D002102:Cadaver; D005260:Female; D005492:Folic Acid / Q000097:blood; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008297:Male; D012016:Reference Values; D016559:Tacrolimus / Q000627:therapeutic use*; D014019:Tissue Donors; D014805:Vitamin B 12 / Q000097:blood
chemical_list: D007166:Immunosuppressive Agents; D006710:Homocysteine; D005492:Folic Acid; D014805:Vitamin B 12; D016559:Tacrolimus